NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02775006,"Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma",https://clinicaltrials.gov/study/NCT02775006,,TERMINATED,"The objective of this study is to investigate the effect of docetaxel monotherapy and the combination of docetaxel intercalated erlotinib in patients with relapsed EGFR wild type, ALK negative non squamous cell carcinoma.",NO,"Carcinoma, Non-small Cell Lung",DRUG: Docetaxel|DRUG: Erlotinib,"progression free survival, from the date of randomization to the first date of progression of disease or of death from any cause up to 24 months after last treatment administration","quantitative and qualitative adverse events, Adverse events will be graded according to NCI Common Toxicity Criteria version 4.03, from the date of randomization until resolution or stabilization of the event and up to 30 days after the last study medication/treatment|response rates, Every six weeks from date of randomization until the date of first documented progression or date of death from any cause up to 24 months after last treatment administration|duration of response, from the date of the first objective status assessment of a complete or partial response to the first date of progression of disease or death from any cause up to 24 months after last treatment administration|overall survival, Evaluation of overall survival (OS), from the date of randomization to the date of death from any cause up to 24 months after last treatment administration","Erlotinib dose level variance in blood, Therefore in patients on erlotinib every 6 weeks through dose levels in blood will be determined, Every six weeks from randomisation up until last treatment administration (up until 48 weeks)",The Netherlands Cancer Institute,Dutch Society of Physicians for Pulmonology and Tuberculosis,ALL,"ADULT, OLDER_ADULT",PHASE3,45,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,NVALT 18,2016-10-14,2019-04,2019-04,2016-05-17,,2019-04-30,"VUmc Medical Center, Amsterdam, Noord-Holland, 1081HV, Netherlands|Gelre Ziekenhuis, Apeldoorn, Netherlands|Amphia Hospital, Breda, Netherlands|Jeroen Bosch Hospital, Den Bosch, Netherlands|Haga, Den Haag, 2545 CH, Netherlands|Albert Schweitzer ziekenhuis, Dordrecht, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Maxima Medisch Centrum, Eindhoven, 5631 BM, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Spaarne Gasthuis, Hoofddorp, 2130 AT, Netherlands|MCL, Leeuwarden, 8934 AD, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Laurentius Hospital, Roermond, Netherlands|St. Fransicus Gasthuis, Rotterdam, 3045 PM, Netherlands|Ikazia, Rotterdam, 3083 AN, Netherlands|Erasmus MC, Rotterdam, Netherlands|Medical Center Haaglanden, the Hague, Netherlands|St. Antonius ziekenhuis, Utrecht, Netherlands|VieCuri Medisch Centrum voor Noord-Limburg, Venlo, Netherlands",
